证券代码：300685 证券简称：艾德生物 公告编号：2025-018 厦门艾德生物医药科技股份有限公司 第四届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 第四届监事会第五次会议于2025年4月19日在厦门市海沧区鼎山路39号公司会议 室以通讯和现场表决相结合的方式召开，会议应到监事3人，实到监事3人，符合 公司章程规定的法定人数。本次会议通知于2025年4月9日以电子邮件等形式发出， 会议的通知和召开符合《公司法》与《公司章程》的规定。本次会议由公司监事 会主席涂东明先生主持。 公司2024年度财务报告已经立信会计师事务所（特殊普通合伙）审计。公司 2024年实现营业收入1,108,948,700.11元，实现归属于上市公司股东的净利润 254,863,444.95元。 二、监事会会议审议情况 1、审议通过《2024年度监事会工作报告》 表决结果：3票赞成，0票反对，0票弃权，本议案获表决通过。 根据2024年监事会的工作情况，监事会起草 ...

证券代码：300685 证券简称：艾德生物 公告编号：2025-017 厦门艾德生物医药科技股份有限公司 第四届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 第四届董事会第六次会议于2025年4月19日在厦门市海沧区鼎山路39号公司会议 室以通讯和现场表决相结合的方式召开，会议应到董事7人，实到董事7人，符合 公司章程规定的法定人数。公司监事和高级管理人员列席了本次会议。本次会议 通知于2025年4月9日以电子邮件等形式发出，会议的通知和召开符合《公司法》 与《公司章程》的规定。本次会议由公司董事长LI-MOU ZHENG先生主持。 二、董事会会议审议情况 1、审议通过《2024年度总经理工作报告》 表决结果：7票赞成，0票反对，0票弃权，本议案获表决通过。 董事会听取了公司总经理所作的《2024年度总经理工作报告》，认为2024年 度公司经营管理层有效执行了董事会、股东大会的各项决议。 详细内容请见公司与本公告同日刊登在中国证监会指定的创业 ...

Financial Performance - The company's operating revenue for 2024 was CNY 1,108,948,700.11, representing a 6.27% increase compared to CNY 1,043,506,694.32 in 2023[16] - The net profit attributable to shareholders for 2024 was CNY 254,863,444.95, a decrease of 2.53% from CNY 261,484,433.37 in 2023[16] - The net profit after deducting non-recurring gains and losses was CNY 233,087,950.27, down 2.45% from CNY 238,952,550.49 in the previous year[16] - The net cash flow from operating activities increased by 14.44% to CNY 341,845,598.08, compared to CNY 298,715,870.41 in 2023[16] - The total assets at the end of 2024 were CNY 2,064,801,711.06, reflecting a 6.71% increase from CNY 1,934,881,553.02 at the end of 2023[16] - The net assets attributable to shareholders increased by 8.22% to CNY 1,843,264,757.86, compared to CNY 1,703,320,906.08 in 2023[16] - The basic earnings per share for 2024 were CNY 0.64, a decrease of 3.03% from CNY 0.66 in 2023[16] - The company reported a total non-operating income of approximately $21.78 million, a decrease from $22.53 million in 2023, and significantly lower than $106.76 million in 2022[22] - The company achieved a revenue of 776.71 million CNY in the domestic market for 2024, earning the title of "National Manufacturing Single Champion" [62] - The revenue from drug clinical research services surged by 81.38% year-on-year, amounting to ¥160,896,610.26, up from ¥88,706,635.50 in 2023[66] - Domestic sales slightly decreased by 1.08% to ¥776,706,105.56, while international sales increased by 28.61% to ¥332,242,594.55[69] - The gross profit margin for the in vitro diagnostic industry was 84.75%, reflecting a year-on-year increase of 0.78%[70] R&D and Innovation - R&D investment reached 216.11 million yuan, accounting for 19.49% of revenue, with a year-on-year growth of 6.35%[53] - The company holds 32 Class III medical device registrations and 68 patents, including 62 invention patents, demonstrating its strong innovation capabilities[53] - The company has developed a comprehensive R&D team of 523 members, focusing on various disciplines to drive efficient project management and innovation[53] - The company is actively involved in research and development, aiming to innovate new products and technologies[126] - The company has completed the development of multiple gene testing kits, enhancing its product line and core competitiveness[81] - The company has launched a new high-throughput gene sequencing instrument, ADx-SEQ200 Plus, which offers a cost-effective solution compared to imported brands[38] - The company has introduced a real-time fluorescence quantitative PCR analyzer, GEMINI, which doubles throughput and simplifies operations for tumor precision diagnostics[38] - The company has developed and received approval for 32 tumor gene detection products, making it a leading enterprise in the industry with the most comprehensive product range[32] Market and Strategic Focus - The company’s strategic focus on precision medicine aligns with the growing demand for tumor gene testing, which has expanded from drug guidance to comprehensive patient lifecycle management[25] - The global cancer incidence is approximately 20 million new cases annually, with China accounting for over 4.8 million new cases, representing about 24% of the global total[26] - The proportion of targeted and immunotherapy drugs in the global oncology drug development pipeline has exceeded 50%, driving rapid growth in related gene testing demand[27] - The company has formed strategic partnerships with over 100 international distributors, enhancing its global operational network [63] - The company has established a direct sales network covering over 500 top hospitals in China, supported by a professional team of nearly 400 people [57] - The company has successfully registered three Class III (CDx) products in overseas markets, including the ROS1 Gene Fusions Detection Kit and the AmoyDx® Pan Lung Cancer Gene PCR panel, which are covered by health insurance in Japan and South Korea[41] Regulatory and Compliance - The regulatory environment is increasingly emphasizing compliance, which is expected to elevate industry standards and concentration, benefiting the company[29] - The company emphasizes strict production and quality control processes, ensuring compliance with regulatory standards and maintaining product quality[48] - The company has established a policy monitoring mechanism to respond to potential regulatory risks[105] - The company has established a comprehensive internal control system, ensuring the legality and compliance of operations, with no significant defects found in financial reporting controls during the reporting period[166] Corporate Governance - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal regulations and the company's articles of association[115] - The company has established specialized committees under the board of directors, including the audit committee and the strategic development committee, to enhance governance effectiveness[114] - The company has a performance evaluation and incentive mechanism that aligns with its development status, ensuring transparency in the hiring and assessment of senior management[116] - The company has experienced changes in its board and management personnel, indicating a shift in governance and operational strategy[122] - The company’s independent directors bring significant academic and industry experience, contributing to its governance[128][129][130] Employee and Training Development - The total number of employees at the end of the reporting period is 1,144, including 683 at the parent company and 461 at major subsidiaries[155] - The professional composition includes 523 technical personnel, 371 sales personnel, and 111 production personnel, among others[156] - The educational background of employees shows 25 with a doctorate, 251 with a master's degree, and 868 with a bachelor's degree or below[156] - The company emphasizes employee development through a structured training system and a scientific incentive mechanism, fostering a positive work environment[175] - The company has actively integrated high-quality training resources to enhance employee skills and overall team capabilities, supporting sustainable development[158] Environmental and Social Responsibility - The company adheres to environmental protection laws and has established a comprehensive environmental management system, focusing on low-carbon and sustainable development[172] - The company actively engages in public welfare activities related to cancer prevention and awareness, contributing to early screening and diagnosis efforts[175] - The company integrates environmental considerations throughout the project lifecycle, aligning with national carbon neutrality goals[175] - The company has not reported any administrative penalties related to environmental issues during the reporting period[172] Cash Dividend and Profit Distribution - The company maintained a cash dividend policy with a total cash dividend amount of ¥117,918,590.70, which represents 100% of the total profit distribution[161] - For the 2024 profit distribution plan, the company proposed a cash dividend of ¥3 per 10 shares (including tax), with no stock dividends or capital reserve transfers[163] - The company’s profit distribution policy has remained unchanged during the reporting period, ensuring clarity and completeness in decision-making processes[161] - The company has implemented a reasonable profit distribution and cash dividend policy, ensuring the protection of investor rights and interests[175] Financial Management and Audit - The company has engaged Lixin Accounting Firm for auditing services, with a fee of 1 million yuan and a continuous service period of 10 years[183] - The company has appointed Lixin Accounting Firm as the internal control auditing firm, with an internal control audit fee of 200,000 yuan[184] - The internal control evaluation report indicates that all evaluated units accounted for 100% of the company's total assets and revenue[168] - The company has committed to strengthen internal controls and improve management levels to ensure normal operations and reduce management risks[179]

Financial Performance - The company's revenue for Q1 2025 was ¥272,090,793.91, representing a 16.63% increase compared to ¥233,288,808.06 in the same period last year[5] - Net profit attributable to shareholders was ¥90,471,778.52, a 40.92% increase from ¥64,199,068.03 year-over-year[5] - The net profit after deducting non-recurring gains and losses was ¥87,223,537.32, up 53.07% from ¥56,981,941.60 in the previous year[5] - Basic and diluted earnings per share were both ¥0.23, a 43.75% increase from ¥0.16 in the previous year[5] - Total operating revenue for the current period reached ¥272,090,793.91, an increase of 16.6% compared to ¥233,288,808.06 in the previous period[20] - Net profit for the current period was ¥90,471,778.52, representing a significant increase of 40.9% from ¥64,199,068.03 in the previous period[21] - The company's profit before tax was ¥101,793,500.12, an increase of 38.3% from ¥73,566,224.34 in the previous period[21] Cash Flow and Liquidity - The net cash flow from operating activities was ¥103,254,852.84, reflecting a 28.14% increase compared to ¥80,577,903.10 in the same period last year[5] - Operating cash flow increased to 103,254,852.84 from 80,577,903.10, a rise of 28.06%[22] - Total cash inflow from operating activities reached 290,859,140.41, compared to 273,690,053.97 in the previous period, marking a 6.25% increase[22] - Cash and cash equivalents at the end of the period decreased to 288,933,634.09 from 323,750,184.55, a drop of 10.76%[23] - The company reported a net increase in cash and cash equivalents of -26,528,201.73, contrasting with a net increase of 122,672,317.88 in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,163,512,829.30, a 4.78% increase from ¥2,064,801,711.06 at the end of the previous year[5] - Total liabilities rose to ¥244,665,855.76, compared to ¥221,536,953.20, indicating an increase of 10.4%[18] - The company's total assets increased to ¥2,163,512,829.30 from ¥2,064,801,711.06, marking a growth of 4.8%[18] - Total current assets increased to ¥1,891,421,886.64 from ¥1,788,399,896.77[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 24,012[12] - The largest shareholder, Forward Investment (Hong Kong) Limited, holds 22.31% of shares, totaling 87,701,616 shares[12] - The total number of shares held by the top ten unrestricted shareholders is 87,701,616, with Forward Investment (Hong Kong) Limited being the largest[13] - The total number of restricted shares at the end of the period is 3,464,606, down from 3,527,230 due to the unlocking of shares[14] - The company has no reported related party relationships or concerted actions among the top shareholders[13] Expenses and Investments - Total operating costs amounted to ¥171,878,070.83, up from ¥167,788,210.58, reflecting a growth of 1.3%[20] - Research and development expenses were ¥41,536,126.88, a decrease of 14.1% from ¥48,363,080.43 in the previous period[20] - The company has a long-term investment of ¥10,497,291.81, down from ¥11,951,810.18[16] - The financial expenses showed a significant improvement, with a net income of -¥10,374,808.85 compared to -¥3,263,353.11 previously[20] Future Plans and Accounting Changes - The company plans to continue its market expansion and product development strategies, although specific details were not disclosed in the provided content[15] - The company plans to adopt new accounting standards starting in 2025, which may impact future financial reporting[24] - The first quarter report was not audited, indicating a preliminary assessment of financial performance[24]

证券代码：300685 证券简称：艾德生物 公告编号：2025-019 厦门艾德生物医药科技股份有限公司 关于 2024 年度利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 以未来实施 2024 年度权益分配方案时股权登记日的总股本（扣除回购专用证券账 户股份）为基数，向全体股东每 10 股派发现金红利 3 元（含税），预计共派发现金红利 117,918,590.701元（含税），不送红股，不以资本公积金转增股本。 一、审议程序 厦门艾德生物医药科技股份有限公司（以下简称"艾德生物"或"公司"） 于 2025 年 4 月 19 日召开第四届董事会第六次会议及第四届监事会第五次会议， 审议通过了《关于 2024 年度利润分配方案的议案》。本议案尚需提交公司 2024 年度股东大会审议。 二、利润分配方案的基本情况 1、本次利润分配为公司 2024 年度利润分配。 2、根据《公司法》和《公司章程》的有关规定，2024 年提取法定盈余公积 金 21,265,143.33 元。经立信会计师事务所（特殊普通合伙）审计，截至 2024 年 ...

艾德生物（300685）公告，2025年第一季度营收为2.72亿元，同比增长16.63%；净利润为9047.18万 元，同比增长40.92%。 ...

Company Overview - Xiamen Ade Biological Technology Co., Ltd. specializes in the research, production, and sales of molecular diagnostic products for precision oncology, providing related testing services [2] - The company's main products include molecular diagnostic reagents for targeted cancer therapy and chemotherapy, which help clinicians develop personalized treatment plans based on the genetic status of cancer patients [2] Financial Performance - For the third quarter of 2024, the company reported a revenue of 848 million yuan, representing a year-on-year increase of 19.84% [3] - The net profit for the same period was 227 million yuan, showing a year-on-year growth of 30.82% [3] - The sales gross margin stood at 84.74% [3] Market Position - As of the latest data, the company's rolling price-to-earnings (PE) ratio is 28.56, while the average PE ratio in the medical device industry is 46.48, and the industry median is 31.96 [1][3] - The total market capitalization of the company is approximately 8.997 billion yuan [1] Institutional Holdings - As of the third quarter of 2024, a total of 264 institutions hold shares in the company, including 263 funds and 1 brokerage, with a total holding of 63.719 million shares valued at 1.453 billion yuan [1]

厦门艾德生物医药科技股份有限公司主营业务系肿瘤精准医疗分子诊断产品的研发、生产及销售，并提 供相关的检测服务。公司产品主要为肿瘤精准医疗靶向用药分子诊断试剂和肿瘤化疗用药分子诊断试剂 两大类，用于检测肿瘤患者相关基因状态，为临床医生制定精准医疗治疗方案提供分子诊断的参考依 据。公司拥有"国家高新技术企业"、"国家企业技术中心"、"博士后科研工作站"、"专精特新'小巨人'企 业"、"国家知识产权示范企业"、"国家发改委基因检测技术应用示范中心"、"福建省肿瘤分子诊断企业 工程技术研究中心"、"福建省肿瘤高通量测序工程研究中心"、"福建省科技小巨人领军企业"、"厦门市 个性化分子诊断重点试验室"等资质，研发部荣获"全国工人先锋号"荣誉称号。公司与北京协和医学 院、北京肿瘤医院、北京大学合作开展"基于外周血分子分型的肺癌个体化诊疗体系建立及临床推广应 用"项目荣获国家科技进步二等奖及教育部科技进步一等奖。"肿瘤个体化基因诊断系列试剂产品的研制 及产业化"项目成果荣获厦门市科学技术进步奖一等奖及福建省科学技术进步奖二等奖。核心专利荣获 国家专利银奖（1项）、福建省专利奖一等奖（2项）。 最新一期业绩显示，2024年三 ...

发明专利名称：一种探针及其适用于高通量测序的对目标区域进行富集的方 法 证券代码：300685 证券简称：艾德生物 公告编号：2025-013 厦门艾德生物医药科技股份有限公司 关于取得日本发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 于近日收到日本特许厅颁发的发明专利证书。具体情况如下： 专利权人：厦门艾德生物医药科技股份有限公司 上述发明专利为公司自主研发，已在公司相关产品上应用。上述专利的取得 不会对公司近期生产经营产生重大影响，但有利于进一步完善公司知识产权保护 体系，充分发挥自主知识产权优势，促进技术创新，增强公司海外市场竞争力， 提升公司的综合实力。 厦门艾德生物医药科技股份有限公司 董 事 会 2025 年 3 月 10 日 专利号：特许第7641118号 专利类型：发明专利 专利申请日：2018年7月18日 专利权期限：自申请日起二十年 ...

证券代码：300685 证券简称：艾德生物 公告编号：2025-012 厦门艾德生物医药科技股份有限公司 关于回购股份注销完成暨股份变动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"）本次 注销的回购股份数量为5,374,840股，占本次注销前公司总股本的1.35%，本次注销完成 后，公司总股本由398,436,809股变更为393,061,969股。 2、经中国证券登记结算有限责任公司深圳分公司确认，公司本次回购股份注销事 宜已于2025年3月4日办理完成。 根据《深圳证券交易所上市公司自律监管指引第9号——回购股份》等相关 法律法规规定，现就本次回购公司股份注销完成的具体情况公告如下： 一、回购股份的实施情况 公司于 2024 年 2 月 26 日召开 2024 年第一次临时股东大会，审议通过了《关 于以集中竞价交易方式回购公司股份的议案》。根据本次回购方案，公司拟使用 自有资金以集中竞价方式回购股份用于注销并减少公司注册资本；回购资金总额 为不低于人民币 10,000 ...